- Home
- PRTC vs DPG Comparison
PRTC vs DPG Comparison
Compare PRTC & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTC
- DPG
- Stock Information
- Founded
- PRTC 2015
- DPG 2011
- Country
- PRTC United States
- DPG United States
- Employees
- PRTC N/A
- DPG N/A
- Industry
- PRTC Biotechnology: Pharmaceutical Preparations
- DPG Trusts Except Educational Religious and Charitable
- Sector
- PRTC Health Care
- DPG Finance
- Exchange
- PRTC Nasdaq
- DPG Nasdaq
- Market Cap
- PRTC 413.5M
- DPG 465.2M
- IPO Year
- PRTC N/A
- DPG N/A
- Fundamental
- Price
- PRTC $16.75
- DPG $12.55
- Analyst Decision
- PRTC Buy
- DPG
- Analyst Count
- PRTC 1
- DPG 0
- Target Price
- PRTC $45.00
- DPG N/A
- AVG Volume (30 Days)
- PRTC 5.6K
- DPG 150.1K
- Earning Date
- PRTC 08-28-2025
- DPG 01-01-0001
- Dividend Yield
- PRTC N/A
- DPG 9.09%
- EPS Growth
- PRTC N/A
- DPG N/A
- EPS
- PRTC 0.20
- DPG N/A
- Revenue
- PRTC $6,391,000.00
- DPG N/A
- Revenue This Year
- PRTC N/A
- DPG N/A
- Revenue Next Year
- PRTC N/A
- DPG N/A
- P/E Ratio
- PRTC $7.61
- DPG N/A
- Revenue Growth
- PRTC 1265.60
- DPG N/A
- 52 Week Low
- PRTC $13.30
- DPG $7.90
- 52 Week High
- PRTC $24.99
- DPG $13.58
- Technical
- Relative Strength Index (RSI)
- PRTC 43.45
- DPG 45.18
- Support Level
- PRTC $15.78
- DPG $12.46
- Resistance Level
- PRTC $16.50
- DPG $12.77
- Average True Range (ATR)
- PRTC 0.57
- DPG 0.12
- MACD
- PRTC -0.18
- DPG -0.04
- Stochastic Oscillator
- PRTC 25.17
- DPG 20.20
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting from a high level of current income, with an emphasis on providing tax-advantaged dividend income.